Abstract
In 2021-23, a resurgence of malaria occurred in the Tororo District of Uganda following a change in formulations used for indoor residual spraying of insecticide (IRS). Prior analyses showed that this increase was temporally associated with the replacement of Anopheles gambiae sensu lato by An. funestus as the dominant local vector. To investigate this association, we used data from a cohort of 422 children in 94 households from 2021-2023 in Tororo District and neighboring Busia District, where IRS was not implemented. Participants underwent passive and monthly active surveillance for infection with Plasmodium falciparum by quantitative PCR. Mosquitoes were collected in each sleeping room in cohort households every 2 weeks using CDC light traps. We assessed the association between spatiotemporally smoothed annualized household entomologic inoculation rates (aEIR) and individual P. falciparum infections using shared frailty models. Overall, each doubling of the aEIR was associated with a 29% increase in the hazard of P. falciparum (adjusted HR 1.29, 95% CI 1.25-1.33). Considering species-specific aEIRs, this effect was primarily driven by An. funestus: a doubling of An. funestus aEIR was associated with a 29% increase in hazard rate (1.29, 1.25-1.34), while the association was smaller for An. gambiae (1.04, 1.01-1.08). These relationships were stronger in Tororo than in Busia. These results support the inference that the replacement of An. gambiae with An. funestus was a driver of increased malaria incidence in Tororo District and demonstrates associations between household-level entomological data and risk of P. falciparum infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding was provided by the National Institutes of Health as part of the International Centers of Excellence in Malaria Research (ICEMR) program (U19AI089674 to GD) and the UCSF Biology of Infectious Diseases Training Program (2T32AI007641-21 to GD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Makerere University School of Medicine Research and Ethics Committee (REF 2019–134), the Uganda National Council for Science and Technology (HS 2700), the London School of Hygiene & Tropical Medicine Ethics Committee (17777), and the University of California, San Francisco Committee on Human Research (257790). Written informed consent was obtained for all participants prior to enrollment into the cohort study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The dataset underlying this study is available in the ClinEpiDB database (DS_17191d35b9).
